Skip to content

Study of the Risk of Ischaemia Following the Creation of an Arteriovenous Fistula

Study of the Risk of Ischaemia Following the Creation of an Arteriovenous Fistula

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06297343
Acronym
MODIFVASC
Enrollment
544
Registered
2024-03-07
Start date
2025-10-20
Completion date
2027-12-31
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Failure

Brief summary

The purpose of this study is to identify functional vascular changes and clinical factors correlated with the occurrence of short- or medium-term hand ischaemia after arteriovenous fistula creation.

Detailed description

This is a non-interventional, prospective, non-randomised, descriptive, single-centre study with no comparator. The study population will be adult patients with chronic renal failure for whom an arteriovenous fistula has been planned. Patients requiring the creation of an arteriovenous fistula by the surgeons at Hôpital Privé des Peupliers will be seen beforehand in the usual pre-operative consultation, during which the surgeon will explain the principle of the operation and the expected benefits/risks. On the day of surgery, patients will undergo the surgical procedure to create an arteriovenous fistula and will be discharged the same day. Patients will be reviewed during post-operative follow-up visits at 1, 6 and 12 months as in standard practice. All the data collected in the study were collected in routine medical practice.

Interventions

PROCEDURECreation of an arteriovenous fistula

Patients will undergo the surgical procedure to create an arteriovenous fistula and will be discharged the same day (outpatient care, or an overnight stay in hospital if they live a long way from the hospital, have multiple pathologies or are socially isolated). An arteriovenous fistula is created under local or general anaesthetic. On the day of the operation, the type of arteriovenous fistula created, the side of the arteriovenous fistula, the location of the arteriovenous fistula and the patency of the arteriovenous fistula will be collected.

Sponsors

Euraxi Pharma
CollaboratorINDUSTRY
GCS Ramsay Santé pour l'Enseignement et la Recherche
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years; * Stage 5 chronic kidney disease, on dialysis or not on dialysis; * Requiring the creation of an arteriovenous fistula; * Membership of a social insurance scheme; * Patient having been informed and having formulated his/her oral non-opposition to participate in the research.

Exclusion criteria

* Contraindication to the proposed surgery ; * Reduced life expectancy in the opinion of the investigator; * Medical or biological conditions which, in the opinion of the investigator, could influence the interpretation of the results of the study or the safety of the patient; * Patient uncooperative with protocol requirements or unable to attend scheduled visits to the centre; * Other surgical or medical intervention planned during the study; * Pregnant or likely to be pregnant (of childbearing age, without effective contraception) or breastfeeding; * Participating in another clinical trial, or in a period of exclusion from another clinical trial; * Patient under guardianship or deprived of liberty.

Design outcomes

Primary

MeasureTime frameDescription
Occurrence of ischaemia of the hand12 monthsNumber and proportion of patients with ischaemia (Yes = stages 1, 2 or 3/No = stage 0) according to the preoperative American Vascular Surgery ischaemia classification : 0 - nothing 1. \- cold hand 2. \- pain on exercise and/or during dialysis 3. \- permanent pain, wound (ulceration, necrosis, gangrene)

Countries

France

Contacts

Primary ContactViviane DUEDAL, MD
v.duedal@gmail.com6 70 80 18 98

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026